Mark Agulnik

Professor of Clinical Medicine

Vice Chair for Faculty Development, Department of Medicine

Section Chief of Sarcomas & Melanoma

Image of Mark Agulnik
Is this your profile? Click to edit

Publications

  • Current unmet needs in locally advanced (unresectable) or metastatic dedifferentiated liposarcoma, the relevance of progression-free survival as clinical endpoint, and expectations for future clinical trial design: an international Delphi consensus report ESMO Open. 2024 Jun 28; 9(7):103487. . View in PubMed
  • Prices and Trends in FDA-Approved Medications for Sarcomas Cancers (Basel). 2024 Apr 18; 16(8). . View in PubMed
  • Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial Lancet. 2024 Apr 13; 403(10435):1460-1471. . View in PubMed
  • Diffuse intra-abdominal sarcomatosis in myxoid pleomorphic liposarcoma BMJ Case Rep. 2024 Jan 16; 17(1). . View in PubMed
  • SMARCA4/BRG1-deficient Uterine Neoplasm With Hybrid Adenosarcoma and Carcinoma Features: Expanding the Molecular-morphologic Spectrum of SMARCA4-driven Gynecologic Malignancies Int J Gynecol Pathol. 2023 Dec 12. . View in PubMed
  • Underreporting of SMARCB1 alteration by clinical sequencing: Integrative patho-genomic analysis captured SMARCB1/INI-1 deficiency in a vulvar yolk sac tumor Gynecol Oncol Rep. 2023 Dec; 50:101294. . View in PubMed
  • State of Cancer Care in America: Achieving Cancer Health Equity Among Sexual and Gender Minority Communities JCO Oncol Pract. 2023 Nov; 19(11):959-966. . View in PubMed
  • Bioinformatic Analysis of Recurrent Genomic Alterations and Corresponding Pathway Alterations in Ewing Sarcoma J Pers Med. 2023 Oct 15; 13(10). . View in PubMed
  • Implications of updated staging system for p16+ oropharyngeal squamous cell carcinoma: Is valuable prognostic information being omitted? Head Neck. 2023 Aug; 45(8):2079-2086.. View in PubMed
  • The Midwest Sarcoma Trials Partnership: Bridging Academic and Community Networks in a Collaborative Approach to Sarcoma J Clin Med. 2023 Mar 29; 12(7). . View in PubMed
  • A phase II trial of regorafenib in patients with advanced Ewing sarcoma and related tumors of soft tissue and bone: SARC024 trial results Cancer Med. 2023 01; 12(2):1532-1539. . View in PubMed
  • Targeted therapies for the treatment of soft tissue sarcoma Front Oncol. 2023; 13:1122508. . View in PubMed
  • Surgical Management of Retroperitoneal Sarcoma Curr Oncol. 2023 04 29; 30(5):4618-4631. . View in PubMed
  • Emerging targeted and cellular therapies in the treatment of advanced and metastatic synovial sarcoma Front Oncol. 2023; 13:1123464. . View in PubMed
  • Role of immunotherapy in chondrosarcoma: A case report and review of the literature Ther Adv Med Oncol. 2023; 15:17588359231199877. . View in PubMed
  • NCCN Guidelines® Insights: Gastrointestinal Stromal Tumors, Version 22022. J Natl Compr Canc Netw. 2022 11; 20(11):1204-1214. . View in PubMed
  • A randomised phase II trial of a trivalent ganglioside vaccine targeting GM2, GD2 and GD3 combined with immunological adjuvant OPT-821 versus OPT-821 alone in metastatic sarcoma patients rendered disease-free by surgery Eur J Cancer. 2022 11; 176:155-163. . View in PubMed
  • Pregnancy outcomes related to the treatment of sarcomas with anthracyclines and/or ifosfamide during pregnancy Cancer Med. 2022 09; 11(18):3471-3478. . View in PubMed
  • Soft Tissue Sarcoma, Version 22022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 07; 20(7):815-833. . View in PubMed
  • Evolving strategies for management of desmoid tumor Cancer. 2022 08 15; 128(16):3027-3040. . View in PubMed
  • Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1 J Clin Oncol. 2022 04 20; 40(12):1291-1300. . View in PubMed
  • Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma Nat Commun. 2022 06 15; 13(1):3406. . View in PubMed
  • All-Internal Limb Lengthening with Simultaneous Corrective Osteotomy After Internal Hemipelvectomy: A Case Report JBJS Case Connect. 2022 04 01; 12(2). . View in PubMed
  • OER-073: A multicenter phase 2 study evaluating the role of pazopanib in angiosarcoma Cancer. 2022 10 01; 128(19):3516-3522. . View in PubMed
  • Optimizing brief, focused assessment of priority symptoms and concerns in recurrent and/or metastatic squamous cell carcinoma of the head and neck: Content validation of the Functional Assessment of Cancer Therapy/National Comprehensive Cancer Network Head and Neck Symptom Index-10 (FHNSI-10) Health Sci Rep. 2021 Dec; 4(4):e401. . View in PubMed
  • An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma Eur J Cancer. 2021 09; 154:201-208. . View in PubMed
  • Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) J Immunother Cancer. 2021 08; 9(8). . View in PubMed
  • Phase II study of pazopanib with oral topotecan in patients with metastatic and non-resectable soft tissue and bone sarcomas Br J Cancer. 2021 08; 125(4):528-533. . View in PubMed
  • Metastatic Myxofibrosarcoma with Durable Response to Temozolomide Followed by Atezolizumab: A Case Report Oncologist. 2021 07; 26(7):549-553. . View in PubMed
  • The Role of Immunotherapy to Overcome Resistance in Viral-Associated Head and Neck Cancer Front Oncol. 2021; 11:649963. . View in PubMed
  • A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas Cancers (Basel). 2020 Jul 11; 12(7). . View in PubMed
  • Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study Lancet Oncol. 2020 11; 21(11):1423-1432. . View in PubMed
  • A phase II study of pazopanib as front-line therapy in patients with non-resectable or metastatic soft-tissue sarcomas who are not candidates for chemotherapy Eur J Cancer. 2020 09; 137:1-9. . View in PubMed
  • Pharmacokinetics of doxorubicin following concomitant intravenous administration of olaratumab (IMC-3G3) to patients with advanced soft tissue sarcoma Cancer Med. 2020 02; 9(3):882-893. . View in PubMed
  • Ectopic hamartomatous thymoma in an immunocompromised male Pathol Res Pract. 2019 Sep; 215(9):152497. . View in PubMed
  • A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcoma Cancer Med. 2019 06; 8(6):2994-3003. . View in PubMed
  • Piloting a Financial Counseling Intervention for Patients With Cancer Receiving Chemotherapy J Oncol Pract. 2019 03; 15(3):e202-e210. . View in PubMed
  • Randomized Double-Blind Phase II Study of Regorafenib in Patients With Metastatic Osteosarcoma J Clin Oncol. 2019 06 01; 37(16):1424-1431. . View in PubMed
  • Elemental Zn and its Binding Protein Zinc-a2-Glycoprotein are Elevated in HPV-Positive Oropharyngeal Squamous Cell Carcinoma Sci Rep. 2019 11 18; 9(1):16965. . View in PubMed
  • Posterior reversible encephalopathy syndrome and takotsubo cardiomyopathy associated with lenvatinib therapy for thyroid cancer: a case report and review Oncotarget. 2018 Jun 15; 9(46):28281-28289. . View in PubMed
  • Growing Role of Regorafenib in the Treatment of Patients with Sarcoma Target Oncol. 2018 08; 13(4):417-422. . View in PubMed
  • Antitumor Activity of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma: An International, Multicenter Study of the Mayo Clinic Phase 2 Consortium (NCI-9742) J Clin Oncol. 2018 05 10; 36(14):1412-1418. . View in PubMed
  • Epithelioid Hemangioendothelioma: Update on Diagnosis and Treatment Curr Treat Options Oncol. 2018 03 15; 19(4):19. . View in PubMed
  • Stereotactic radiosurgery for brain metastases from primary head and neck carcinomas: a retrospective analysis J Neurooncol. 2017 Aug; 134(1):197-203. . View in PubMed
  • Olaratumab for advanced soft tissue sarcoma Expert Rev Clin Pharmacol. 2017 Jul; 10(7):699-705. . View in PubMed
  • Targeted Therapy in Head and Neck Cancer: An Update on Current Clinical Developments in Epidermal Growth Factor Receptor-Targeted Therapy and Immunotherapies Drugs. 2017 May; 77(8):843-857. . View in PubMed
  • Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials Oncotarget. 2017 Jan 31; 8(5):8910-8920. . View in PubMed
  • Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial Lancet Oncol. 2017 08; 18(8):1089-1103. . View in PubMed
  • NCCN Guidelines Insights: Bone Cancer, Version 22017. J Natl Compr Canc Netw. 2017 02; 15(2):155-167. . View in PubMed
  • A phase II study of tivozanib in patients with metastatic and nonresectable soft-tissue sarcomas Ann Oncol. 2017 01 01; 28(1):121-127. . View in PubMed
  • Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Lancet. 2016 Jul 30; 388(10043):488-97. . View in PubMed
  • Phase II study of MLN8237 (Alisertib) in advanced/metastatic sarcoma Ann Oncol. 2016 10; 27(10):1855-60. . View in PubMed
  • Dose-escalation study of a second-generation non-ansamycin HSP90 inhibitor, onalespib (AT13387), in combination with imatinib in patients with metastatic gastrointestinal stromal tumour Eur J Cancer. 2016 07; 61:94-101. . View in PubMed
  • PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma J Clin Oncol. 2016 11 10; 34(32):3898-3905. . View in PubMed
  • Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives Drug Des Devel Ther. 2016; 10:873-84. . View in PubMed
  • Whole-Field Sequential Intensity-Modulated Radiotherapy for Local-Regional Advanced Head-and-Neck Squamous Cell Carcinoma Am J Clin Oncol. 2015 Dec; 38(6):588-94. . View in PubMed
  • A Phase Ib/II Study of Gemcitabine and Docetaxel in Combination With Pazopanib for the Neoadjuvant Treatment of Soft Tissue Sarcomas Oncologist. 2015 Nov; 20(11):1245-6. . View in PubMed
  • Targeted therapies in advanced differentiated thyroid cancer Cancer Treat Rev. 2015 Sep; 41(8):690-8. . View in PubMed
  • Effect of induction chemotherapy on swallow physiology and saliva production in patients with head and neck cancer: a pilot study Head Neck. 2015 Apr; 37(4):567-72. . View in PubMed
  • Targeted therapy and promising novel agents for the treatment of advanced soft tissue sarcomas Expert Opin Investig Drugs. 2015; 24(11):1409-18. . View in PubMed
  • Examination of national lymph node evaluation practices for adult extremity soft tissue sarcoma J Surg Oncol. 2014 Nov; 110(6):682-8. . View in PubMed
  • Phase III randomized trial of induction chemotherapy in patients with N2 or N3 locally advanced head and neck cancer J Clin Oncol. 2014 Sep 01; 32(25):2735-43. . View in PubMed
  • Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer Thyroid. 2014 Sep; 24(9):1329-40. . View in PubMed
  • Understanding rechallenge and resistance in the tyrosine kinase inhibitor era: imatinib in gastrointestinal stromal tumor Am J Clin Oncol. 2014 Aug; 37(4):417-22. . View in PubMed
  • Occult primary, version 32014. J Natl Compr Canc Netw. 2014 Jul; 12(7):969-74. . View in PubMed
  • Assessment of multimodality therapy use for extremity sarcoma in the United States J Surg Oncol. 2014 Apr; 109(5):395-404. . View in PubMed
  • Targeted treatment of head and neck squamous-cell carcinoma: potential of lapatinib Onco Targets Ther. 2014; 7:245-51. . View in PubMed
  • Effect of recombinant human deoxyribonuclease on oropharyngeal secretions in patients with head-and-neck cancers treated with radiochemotherapy Int J Radiat Oncol Biol Phys. 2013 Oct 01; 87(2):282-9. . View in PubMed
  • Bone cancer J Natl Compr Canc Netw. 2013 Jun 01; 11(6):688-723. . View in PubMed
  • Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial Lancet Oncol. 2013 Apr; 14(4):371-82. . View in PubMed
  • Promising new molecular targeted therapies in head and neck cancer Drugs. 2013 Mar; 73(4):315-25. . View in PubMed
  • A phase II study of tasisulam sodium (LY573636 sodium) as second-line or third-line treatment for patients with unresectable or metastatic soft tissue sarcoma Invest New Drugs. 2013 Feb; 31(1):145-51. . View in PubMed
  • An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas Ann Oncol. 2013 Jan; 24(1):257-63. . View in PubMed
  • Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC Onco Targets Ther. 2013; 6:135-43. . View in PubMed
  • New approaches to EGFR inhibition for locally advanced or metastatic squamous cell carcinoma of the head and neck (SCCHN) Med Oncol. 2012 Dec; 29(4):2481-91. . View in PubMed
  • Phase II study of gefitinib adaptive dose escalation to skin toxicity in recurrent or metastatic squamous cell carcinoma of the head and neck Oral Oncol. 2012 Sep; 48(9):887-92. . View in PubMed
  • Advances in adjuvant therapy of gastrointestinal stromal tumors Curr Oncol Rep. 2012 Aug; 14(4):327-32. . View in PubMed
  • New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma Cancer. 2012 Mar 15; 118(6):1486-97. . View in PubMed
  • Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib Chemotherapy. 2012; 58(1):30-3. . View in PubMed
  • Management of neuroendocrine tumors of unknown origin J Natl Compr Canc Netw. 2011 Dec; 9(12):1397-402; quiz 1403. . View in PubMed
  • NCCN Clinical Practice Guidelines Occult primary J Natl Compr Canc Netw. 2011 Dec; 9(12):1358-95. . View in PubMed
  • Targeted therapies in bone sarcomas: current approach and future directions Expert Opin Investig Drugs. 2011 Jul; 20(7):973-9. . View in PubMed
  • Oral complications of targeted cancer therapies: a narrative literature review Oral Oncol. 2011 Jun; 47(6):441-8. . View in PubMed
  • Head and neck cancer: changing epidemiology and public health implications Oncology (Williston Park). 2010 Sep; 24(10):915-9924. . View in PubMed
  • Treatment of multiple keratoacanthomas with erlotinib Int J Clin Oncol. 2010 Aug; 15(4):413-5. . View in PubMed
  • Dermatologic infections in cancer patients treated with epidermal growth factor receptor inhibitor therapy J Natl Cancer Inst. 2010 Jan 06; 102(1):47-53. . View in PubMed
  • A phase II study of pazopanib in patients with recurrent or metastatic invasive breast carcinoma: a trial of the Princess Margaret Hospital phase II consortium Oncologist. 2010; 15(8):810-8. . View in PubMed
  • Fluorescence in situ hybridization gene amplification analysis of EGFR and HER2 in patients with malignant salivary gland tumors treated with lapatinib Head Neck. 2009 Aug; 31(8):1006-12. . View in PubMed
  • Increased risk of high-grade dermatologic toxicities with radiation plus epidermal growth factor receptor inhibitor therapy Cancer. 2009 Mar 15; 115(6):1286-99. . View in PubMed
  • Occult primary J Natl Compr Canc Netw. 2008 Nov; 6(10):1026-60. . View in PubMed
  • Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis : results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center Cancer. 2008 Sep 15; 113(6):1446-52. . View in PubMed
  • The role of inhibitors of the epidermal growth factor in management of head and neck cancer J Natl Compr Canc Netw. 2008 Aug; 6(7):696-706. . View in PubMed
  • Nasopharyngeal carcinoma: current management, future directions and dental implications Oral Oncol. 2008 Jul; 44(7):617-27. . View in PubMed
  • Salivary gland malignancies: the role for chemotherapy and molecular targeted agents Semin Oncol. 2008 Jun; 35(3):309-19. . View in PubMed
  • New therapeutic options in gastrointestinal stromal tumors Oncology (Williston Park). 2008 Feb; 22(2):206-11; discussion 215-6219. . View in PubMed
  • Molecularly targeted therapies in adult soft tissue sarcomas: present approach and future directions Expert Opin Ther Targets. 2008 Feb; 12(2):197-207. . View in PubMed
  • Promising newer molecular-targeted therapies in head and neck cancer Drugs. 2008; 68(12):1609-19. . View in PubMed
  • Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands J Clin Oncol. 2007 Sep 01; 25(25):3978-84. . View in PubMed
  • Phase II trial of sorafenib in patients with recurrent or metastatic squamous cell carcinoma of the head and neck or nasopharyngeal carcinoma J Clin Oncol. 2007 Aug 20; 25(24):3766-73. . View in PubMed
  • Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib J Clin Oncol. 2007 Jun 01; 25(16):2184-90. . View in PubMed
  • Malignancies of the head and neck: the role for molecular targeted agents Expert Opin Ther Targets. 2007 Feb; 11(2):207-17. . View in PubMed
  • The changing management of low-grade astrocytomas and oligodendrogliomas Hematol Oncol Clin North Am. 2006 Dec; 20(6):1249-66. . View in PubMed
  • Impact and perceptions of mandatory tumor biopsies for correlative studies in clinical trials of novel anticancer agents J Clin Oncol. 2006 Oct 20; 24(30):4801-7. . View in PubMed
  • Recent advances in the treatment of oligodendrogliomas Curr Neurol Neurosci Rep. 2006 May; 6(3):212-7. . View in PubMed
  • Multidisciplinary Symposium on Head and Neck Cancer2 December 2005, Philadelphia, PA, USA. Expert Opin Pharmacother. 2006 Mar; 7(4):489-94. . View in PubMed
  • Paclitaxel, carboplatin, and concomitant radiotherapy for resected patients with high risk head and neck cancer J Chemother. 2005 Apr; 17(2):237-41. . View in PubMed
  • State-of-the-art management of nasopharyngeal carcinoma: current and future directions Br J Cancer. 2005 Mar 14; 92(5):799-806. . View in PubMed
  • An update on the systemic therapy of malignant salivary gland cancers: role of chemotherapy and molecular targeted agents Curr Med Chem Anticancer Agents. 2004 Nov; 4(6):543-51. . View in PubMed
  • Integrative tumor board: colon cancer with liver metastases: case presentation Integr Cancer Ther. 2003 Jun; 2(2):166-198. . View in PubMed
  • Malignant lymphoma of mucosa-associated lymphoid tissue of the lacrimal gland: case report and review of literature Am J Clin Oncol. 2001 Feb; 24(1):67-70. . View in PubMed
  • Resource utilization for peritoneal catheter placement ASAIO J. 2001 Jan-Feb; 47(1):97-8. . View in PubMed